𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Oxaliplatin plus raltitrexed in patients with advanced colorectal carcinoma : Results of a Phase I–II trial

✍ Scribed by Werner Scheithauer; Gabriela V. Kornek; Herbert Ulrich-Pur; Melitta Penz; Markus Raderer; Tomas Salek; Karin Haider; Werner Kwasny; Dieter Depisch

Publisher
John Wiley and Sons
Year
2001
Tongue
English
Weight
88 KB
Volume
91
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A Phase II trial of nolatrexed dihydroch
A Phase II trial of nolatrexed dihydrochloride in patients with advanced hepatocellular carcinoma
✍ Keith Stuart; Judy Tessitore; Jeff Rudy; Neil Clendennin; Amanda Johnston 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 70 KB 👁 1 views

## BACKGROUND. Inoperable hepatocellular carcinoma is an incurable malignancy with no accepted standard therapy. Chemotherapy has demonstrated occasional responses and the need is great for a new and effective agent. Therefore the authors conducted this Phase II trial of a novel thymidylate syntha

A Phase II trial of high dose epirubicin
A Phase II trial of high dose epirubicin in patients with advanced breast carcinoma
✍ Kathy D. Miller; Nikhil Munshi; David Loesch; Lawrence H. Einhorn; George W. Sle 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 82 KB 👁 1 views

## BACKGROUND. Anthracyclines are among the most active drugs in the treatment of breast carcinoma and exhibit a steep dose-response curve in vitro. This trial was performed to determine the efficacy and toxicity of epirubicin in the treatment of patients with advanced breast carcinoma when adminis

A phase II trial of weekly high dose con
A phase II trial of weekly high dose continuous infusion 5-fluorouracil plus oral leucovorin in patients with advanced colorectal cancer
✍ Enrique Aranda; Andrés Cervantes; Javier Dorta; Esperanza Blanco; Carlos Fernánd 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 419 KB 👁 1 views

Background. In a previous Phase I1 trial, the authors showed that a weekly continuous infusion of 5-fluorouracil (5-FU) at a dose of 3.5 g/mz for 48 hours is an active treatment for advanced colorectal cancer. The overall response rate was 38.5%, and the median survival was 12 months. These data wer

Activity of multitargeted antifolate (pe
Activity of multitargeted antifolate (pemetrexed disodium, LY231514) in patients with advanced colorectal carcinoma : Results from a Phase II study
✍ William John; Joel Picus; Charles D. Blanke; Jeffery W. Clark; Lawrence N. Schul 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 80 KB 👁 1 views

## BACKGROUND. The aim of this study was to confirm the activity and assess the safety profile of multitargeted antifolate (MTA) for patients with metastatic colorectal adenocarcinoma. ## METHODS. Forty-six patients were enrolled in the study, 35 with colon and 11 with rectal carcinoma. Adjuvant